ライフサイエンスコーパス: vitrectomy

1 ntravitreal antibiotic administration and/or vitrectomy).

2 al ganciclovir and laser photocoagulation or vitrectomy.

3 ith intravitreal antibiotics and 4 underwent vitrectomy.

4 h as cataract surgery combined with anterior vitrectomy.

5 o 4 times daily for 3 days before pars plana vitrectomy.

6 2 consecutive patients undergoing pars plana vitrectomy.

7 pneumatic retinopexy, scleral buckling, and vitrectomy.

8 ears), 144 (0.02%) developed an MH requiring vitrectomy.

9 lar invasion or extrascleral extension after vitrectomy.

10 achieved in 2 of 5 patients after the first vitrectomy.

11 ocular lens (IOL) implantation, and anterior vitrectomy.

12 mendation of its adoption in microincisional vitrectomy.

13 nt option for eyes with open holes following vitrectomy.

14 r several weeks before undergoing diagnostic vitrectomy.

15 s underwent more than 1 FNAB, biopsy, and/or vitrectomy.

16 surgery reattachment rate may be higher with vitrectomy.

17 iled closure or reopened holes after primary vitrectomy.

18 incisional vitrectomy compared with standard vitrectomy.

19 atient with keratoconus following pars plana vitrectomy.

20 idiopathic MH requiring surgical repair with vitrectomy.

21 her incidence of glaucoma after lens-sparing vitrectomy.

22 use of the trocars and cannulas as in adult vitrectomies.

23 itrectomies, and MERSI cases were diagnostic vitrectomies.

24 Ocular therapy in 8 patients included vitrectomy (1), laser photocoagulation (4), intravitreal

25 dophthalmitis (2/19, 10.5%), post-pars plana vitrectomy (1/19, 5.3%), and post-scleral buckle exposur

26 e phacoemulsification (20.8%) and pars plana vitrectomy (10.4%).

27 seventeen patients (22%) underwent same-day vitrectomy, 131 patients (23%) underwent PPV within 1 we

28 ent was vitreous tap (49; 78%) or pars plana vitrectomy (14; 22%); all received intravitreal antibiot

29 o assess the surgical outcomes of pars plana vitrectomy, 180 degrees inferior retinotomy and silicone

30 CSF in the patients who chose limited vitrectomy (2.51 +/- 0.46 %W; range 2.03-3.06 %W) was 41

31 ents had an ophthalmic procedure, pars plana vitrectomy (4.8%) being the most common one.

32 toward vitrectomy with a distribution of 83% vitrectomy, 5% scleral buckling, and 12% pneumatic retin

33 Within 1 year of vitrectomy, 52.1% of phakic eyes had undergone cataract

34 penetrating keratoplasty was associated with vitrectomy (57 eyes, group 3).

35 rent Procedural Terminology 67015, 67025), a vitrectomy (67036), or an intravitreal antibiotic inject

36 amond-dusted membrane scraper at the time of vitrectomy achieves high rates of MH closure.

37 Women had 24% decreased odds of undergoing vitrectomy (adjusted odds ratio [OR], 0.76; 95% confiden

38 Three cases among those undergoing vitrectomy after 3 months were complicated by retinal de

39 ular holes and vitreomacular traction during vitrectomy after intravitreal ocriplasmin injection with

40 =20/200 vs. >/=20/40, aHR, 1.47); pars plana vitrectomy (aHR, 1.87); history of OHT in the other eye:

41 ilure rate compared with those who underwent vitrectomy alone (n = 2235; P = 0.048).

42 Pars plana vitrectomy alone with complete drainage of subretinal fl

43 Vitrectomy alone without gas tamponade and laser photoco

44 Large or giant retinal tears treated with vitrectomy also had a significantly lower failure rate v

45 idiopathic MH requiring surgical repair with vitrectomy among a large group of managed care plan bene

46 88 logMAR; range, -0.14 to 2.7 logMAR) after vitrectomy and 0.76 logMAR (mean, 1.14 logMAR; range, 0.

47 Combined 25-gauge posterior vitrectomy and 25-gauge trans-vitrector port needle aspi

48 drome, 2 (12%) were aphakic after pars plana vitrectomy and 4 (24%) were aphakic after surgical inter

49 toid macular changes treated with pars plana vitrectomy and epiretinal and internal limiting membrane

50 glaucoma, underwent surgery with pars plana vitrectomy and epiretinal and internal limiting membrane

51 itrated laser photocoagulation combined with vitrectomy and gas tamponade can safely create an effect

52 ser photocoagulation followed immediately by vitrectomy and gas tamponade.

53 pillary laser photocoagulation combined with vitrectomy and gas tamponade.

54 Pars plana vitrectomy and ILM peeling have beneficial effects on th

55 r intraocular lens (PCIOL) before pars plana vitrectomy and lensectomy.

56 Patients underwent pars plana vitrectomy and peeling of the internal limiting membrane

57 tomy, and 3 eyes (15.8%) required pars plana vitrectomy and posterior capsulotomy.

58 The last patient had a pars plana vitrectomy and silicone oil instillation combined with p

59 may facilitate visualization during anterior vitrectomy and the IOL may be used as a pupillary barrie

60 omy was beneficial in pseudophakic eyes, and vitrectomy and TSCPC were beneficial in refractory cases

61 During vitrectomy and under scleral indentation at 5-o'clock po

62 TMC and BMC were therapeutic and diagnostic vitrectomies, and MERSI cases were diagnostic vitrectomi

63 rior hydrocephalus, 1 uveitis and pars plana vitrectomy, and 1 juvenile open-angle glaucoma) and 21 o

64 All 15 patients had prior pars plana vitrectomy, and 14 patients (93%) had no lens capsule.

65 Novel approaches for lens fragment removal, vitrectomy, and lens implantation have expanded the avai

66 reous composition and degradation, improving vitrectomy, and pharmacological vitreolysis.

67 ain from baseline, nonsurgical FTMH closure, vitrectomy, and Visual Function Questionnaire 25 (VFQ-25

68 ncident DR requiring laser photocoagulation, vitrectomy, and/or antiangiogenic therapy confirmed by a

69 Temporary keratoprostheses and endoscopic vitrectomies are valuable surgical tools in these challe

70 Systemic evaluation and visual outcome after vitrectomy are discussed.

71 Absence of lens capsule and prior vitrectomy are risk factors for migration of the DEX imp

72 s study evaluated a technique using 25-gauge vitrectomy as an adjunct to needle biopsy immediately be

73 osis, filtering surgery before keratoplasty, vitrectomy associated with keratoplasty, and filtering s

74 ) and those who had partial PPVs or anterior vitrectomies (AVs) at the time of KPro implantation (n =

75 Cumulative probability of vitrectomy by 16 weeks was 12% with ranibizumab vs 17% w

76 complete panretinal photocoagulation without vitrectomy by 16 weeks was 44% and 31%, respectively (P

77 s that compared microincisional and standard vitrectomy by searching MEDLINE and EMBASE up to Novembe

78 blood culture bottles for culture of diluted vitrectomy cassette vitreous provides the highest number

79 Diluted vitrectomy cassette vitreous specimens from March 25, 20

80 Five of 6 had surgeries such as vitrectomy, cataract extraction, or a procedure for glau

81 Scleral buckle and vitrectomy combined with belt buckle were performed in 4

82 yes with MHRD in 27 patients who underwent a vitrectomy combined with ILMR and ABC and were followed

83 A vitrectomy combined with ILMR and ABC is effective for c

84 tomy, posterior capsulorrhexis, and anterior vitrectomy combined with primary intraocular lens implan

85 risk of endophthalmitis for microincisional vitrectomy compared with standard vitrectomy.

86 vitrectomy rates (and risks associated with vitrectomy) compared with saline for vitreous hemorrhage

87 iated with IOP elevation included pars plana vitrectomy, contralateral IOP elevation (adjusted hazard

88 After vitrectomy, CSF improved by an average of 43.2%, normali

89 s treated with endoresection or endodrainage-vitrectomy developed less radiation retinopathy (30.5% a

90 ment for retinal photocoagulation therapy or vitrectomy, development of proliferative retinopathy, or

91 uge of instrumentation, and history of prior vitrectomy did not result in significant differences amo

92 der the curve, peripheral visual field loss, vitrectomy, DME development, and retinal neovascularizat

93 oth eyes and underwent unilateral pars plana vitrectomy due to postcataract endophthalmitis.

94 ence tomography in patients after pars plana vitrectomy due to postcataract endophthalmitis.

95 ic ages), prior cataract surgery, pars plana vitrectomy, duration of uveitis >/=6 months, contralater

96 All patients underwent a vitrectomy during the course of their treatment, and all

97 er general anesthesia with standard 25-gauge vitrectomy equipment.

98 lanoma underwent complete 25-gauge posterior vitrectomy followed by transvitrector port fine-needle a

99 High anatomical success rate of primary vitrectomy for complex RRD with either gas or SO tampona

100 Vitrectomy for complications of choroidal tumor biopsy i

101 eyes from 20 patients undergoing pars plana vitrectomy for complications of PDR.

102 linical suspicion with subsequent diagnostic vitrectomy for cytologic analysis and collaboration with

103 c trimming of a retroprosthetic membrane; or vitrectomy for endophthalmitis with visualization throug

104 ry and healing of outer retinal layers after vitrectomy for foveal detachment associated with optic d

105 To evaluate visual outcomes after vitrectomy for intraocular hemorrhages secondary to trau

106 20 patients (all male) underwent pars plana vitrectomy for intraocular hemorrhages secondary to trau

107 g a standard 20-gauge or 23-gauge pars plana vitrectomy for intraocular hemorrhages secondary to trau

108 ternal limiting membrane is necessary during vitrectomy for macular pucker.

109 ith a diamond-dusted membrane scraper during vitrectomy for MH repair.

110 h high myopia (HR, 6.12; 95% CI, 5.84-6.41), vitrectomy for perioperative capsular rupture (HR, 4.36;

111 939 eyes of 834 patients undergoing primary vitrectomy for proliferative diabetic retinopathy at 16

112 assess the risks and benefits of pars plana vitrectomy for proliferative diabetic retinopathy, but c

113 combined phacoemulsification and pars plana vitrectomy for retinal detachment and later silicone oil

114 a cilium found in the vitreous cavity during vitrectomy for rhegmatogenous retinal detachment 40 year

115 % retinal attachment was achieved by another vitrectomy for rhegmatogenous retinal detachment that oc

116 Vitrectomy for symptomatic vitreous floaters carries sig

117 formed at the slit lamp or during pars plana vitrectomy for telangiectasia visible at the retinal vas

118 A total of 28 eyes in 20 patients undergoing vitrectomy for Terson syndrome secondary to traumatic br

119 ncing vitreous hemorrhage, or (5) undergoing vitrectomy for the treatment of PDR.

120 Ten patients underwent vitrectomy for visually significant vitreous amyloidosis

121 While performing a vitrectomy for vitreomacular traction posterior hyaloid

122 pontaneous closure of the macular hole after vitrectomy for vitreomacular traction.

123 pontaneous closure of the macular hole after vitrectomy for vitreomacular traction.

124 formation and its spontaneous closure after vitrectomy for vitreomacular traction.

125 hese patients required subsequent pars plana vitrectomy for worsening clinical course.

126 Five patients required pars plana vitrectomy for worsening vitritis.

127 l consecutive patients who underwent primary vitrectomy, from January 2009 to December 2014, at 4 ter

128 te of the initial procedure was lower in the vitrectomy group compared with the scleral buckle group

129 nd P = .06 (comparator group vs endodrainage-vitrectomy group).

130 ening complications (P = 0.051) in the total vitrectomy group.

131 Diabetic vitrectomy has an appreciable complication rate, particu

132 Recently, 25-gauge vitrectomy has become more popular.

133 ed into 2 groups: Group 1 (20 eyes) received vitrectomy, ILM peeling within the arcade area, and air-

134 itreal antibiotics in 4 eyes, and pars plana vitrectomy in 4 eyes.

135 atment in 57 of 63 (90%) eyes and pars plana vitrectomy in 6 of 63 (10%) eyes.

136 nd posterior capsules combined with anterior vitrectomy in children with cataract.

137 icosteroids, antiviral medication, and early vitrectomy in many patients, visual outcomes typically w

138 tool in evaluating the risk-benefit ratio of vitrectomy in patients with large symptomatic vitreous f

139 to traumatic brain injury, and the timing of vitrectomy in relation to the inciting intracranial even

140 4 times daily, for 3 days before pars plana vitrectomy in the first 12 consecutive eyes.

141 orrhage group; all other eyes that underwent vitrectomy in the same period, without delayed suprachor

142 Median time to vitrectomy in the same week group was 5 days, compared w

143 led intraoperative viewing during pars plana vitrectomy include posterior segment disease with signif

144 All patients underwent pars plana vitrectomy, internal limiting membrane peeling, and 17%

145 Fourteen eyes underwent pars plana vitrectomy, internal limiting membrane peeling, and gas

146 phthalmic ultrasound, angioinhibitory drugs, vitrectomy, intraocular gases, and many others.

147 uid exchange, and Group 2 (20 eyes) received vitrectomy, inverted ILM inserted into the macular hole,

148 Vitrectomy is effective in the repair of RD resulting fr

149 adjuvant treatment option, the endodrainage-vitrectomy is recommended in patients who are ineligible

150 y, a large tear, or a giant tear is present, vitrectomy is the procedure of choice.

151 age 4A, 4B, and 5 who underwent lens-sparing vitrectomy (LSV) between 1992 and 2013.

152 tors related to, glaucoma after lens-sparing vitrectomy (LSV) surgery in advanced retinopathy of prem

153 A complete pars plana vitrectomy may be required in order to reposition the di

154 Vitrectomy may be successful in closing the macular hole

155 onade and 49 eyes (11.7%) undergoing further vitrectomy (median follow-up, 6.9 months); 17.9% of 127

156 onade and 78 eyes (15.0%) undergoing further vitrectomy (median follow-up, 7.1 months); 21.2% of 126

157 surgery and at 1, 3, 6, and 12 months after vitrectomy/membrane peel without chromodissection.

158 ry (n = 73) or combined cataract surgery and vitrectomy (n = 6).

159 likely to have posterior capsular tear with vitrectomy (odds ratio [OR] 1.8, P = .03) and sulcus int

160 The surgical management using pars plana vitrectomy offers the most effective approach for VMT, b

161 Pars plana vitrectomy offers theoretical advantages but is generall

162 itreous specimens from patients subjected to vitrectomy or buckling surgery for RRD.

163 inal membranes may be associated with either vitrectomy or endophthalmitis in the history.

164 ed to identify all enrollees who underwent 1 vitrectomy or more each year from 2001 through 2012.

165 brain injury, irrespective of the timing of vitrectomy or of preoperative visual acuity.

166 re all patients who required re-irradiation, vitrectomies, or tumor resections; and those whose treat

167 t with surgical treatment (scleral buckling, vitrectomy, or pneumatic retinopexy).

168 nagement strategy, surgical characteristics, vitrectomy outcomes, and significance of systemic evalua

169 eligible enrollees, 40 892 (0.4%) underwent vitrectomy over the 12-year period.

170 Fifteen eyes underwent vitrectomy owing to the presence of ERM (10 eyes), large

171 .01), whether spontaneously (P < .01) or via vitrectomy (P = .04), but VA did not improve in holes th

172 with combined cataract surgery and anterior vitrectomy (P = .051), although only 0.08% of eyes had t

173 n treated with a scleral buckle alone versus vitrectomy (P = 0.0017).

174 Endoscopic vitrectomy, particularly with the recent advent of 23-ga

175 Rates of vitrectomy per 1000 enrollees were computed each year fr

176 noma as a late complication of biopsy and/or vitrectomy performed at referring institutions and then

177 anagement options for VMT include pars plana vitrectomy, pneumatic vitreolysis, enzymatic vitreolysis

178 buckling (SB group - 12 eyes), or pars plana vitrectomy (PPV group - 21 eyes).

179 disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39;

180 ither by scleral buckling (SB) or pars plana vitrectomy (PPV) according to the topography and clinica

181 All cases were treated with pars plana vitrectomy (PPV) and a double silicone oil endotamponade

182 26 men) that underwent successful pars plana vitrectomy (PPV) and internal limiting membrane (ILM) pe

183 Nondiabetic eyes undergoing pars plana vitrectomy (PPV) and silicone oil tamponade with or with

184 Venous air embolism (VAE) during pars plana vitrectomy (PPV) can occur owing to improper positioning

185 Pars plana vitrectomy (PPV) continues to demonstrate efficacy as a

186 raphy data (iOCT) in all steps of pars plana vitrectomy (PPV) for non-RRD in MGS, in order to follow

187 al photocoagulation (PRP), or (3) pars plana vitrectomy (PPV) for PDR; and study eye changes on the D

188 auge transconjunctival sutureless pars plana vitrectomy (PPV) for serous macular detachment associate

189 n in diabetic subjects undergoing pars plana vitrectomy (PPV) for severe manifestations of active pro

190 es with subhyaloid hemorrhage and pars plana vitrectomy (PPV) for the eyes with FTMH and epimacular m

191 longer-term outcomes of 27-gauge pars plana vitrectomy (PPV) in eyes with posterior segment disease.

192 ss of prophylactic laser or early pars plana vitrectomy (PPV) in preventing retinal detachment (RD) r

193 Pars plana vitrectomy (PPV) is preferred surgical procedure for the

194 s with IOFBs that we extracted by pars plana vitrectomy (PPV) over a 5-year period.

195 son, vitreous samples obtained by pars plana vitrectomy (PPV) resulted in fungus-positive cytologic r

196 When pars plana vitrectomy (PPV) was selected as the primary procedure,

197 403 operations, 2693 (79.1%) were pars plana vitrectomy (PPV), 413 (12.1%) were retinopexy with a scl

198 re compared, including repeat PR, pars plana vitrectomy (PPV), and combined scleral buckle (SB) plus

199 pexy (PR), scleral buckling (SB), pars plana vitrectomy (PPV), and laser prophylaxis were used to qua

200 prior to the study, a history of pars plana vitrectomy (PPV), and less than 1 year of follow-up.

201 more than 180 degrees by combined pars plana vitrectomy (PPV), encircling scleral buckle, 360 degrees

202 e (C(3)F(8)) as an alternative to pars plana vitrectomy (PPV).

203 ents (67%) subsequently underwent pars plana vitrectomy (PPV).

204 Symptomatic patients underwent pars plana vitrectomy (PPV).

205 Twenty-six eyes underwent pars plana vitrectomy (PPV).

206 ntravitreal antifungal injection, pars plana vitrectomy (PPV).

207 All 15 eyes underwent pars plana vitrectomy (PPV): 6 for vitreous hemorrhage (VH), 1 for

208 fety of transconjuctival 23-gauge pars plana vitrectomy(PPV) for removal of intraocular foreign bodie

209 To determine the impact of total pars plana vitrectomies (PPVs) with peripheral shaving of the vitre

210 Either anterior or posterior vitrectomy procedures were performed with 20-, 23-, or 2

211 From a total of 4852 vitrectomy procedures, 39 cases of delayed suprachoroida

212 During this same period, the vitrectomy rate among persons with diabetes mellitus dec

213 ascular endothelial growth factor can reduce vitrectomy rates (and risks associated with vitrectomy)

214 Whether vitrectomy rates after saline or ranibizumab injection a

215 wever, among persons with diabetes mellitus, vitrectomy rates declined substantially over this period

216 Overall vitrectomy rates increased 31% from 2001 to 2012 (from 1

217 Overall, we observed an increase in the vitrectomy rates per 1000 enrollees in this large manage

218 who received conventional therapy underwent vitrectomy, retinal-detachment surgery, or both (adjuste

219 ogic diagnoses of therapeutic and diagnostic vitrectomy samples and their processing protocols from 3

220 a (VRL) and their diagnostic potential in 75 vitrectomy samples of 69 patients, and validated our res

221 Cytologic evaluation of therapeutic vitrectomy samples provides a valuable baseline of nonpa

222 ogic diagnoses of diagnostic and therapeutic vitrectomy samples.

223 Currently, surgical techniques, including vitrectomy, scleral buckle, and pneumatic retinopexy, ar

224 terior dislocations necessitating pars plana vitrectomy; secondary implantations for aphakia; and iri

225 Previous scleral buckling or pars plana vitrectomy seem to have no impact on the success of the

226 Most vitrectomies showed negative results for malignancy: 99.

227 gnificantly improves the diagnostic yield of vitrectomy specimens.

228 an that recommended from the Endophthalmitis Vitrectomy Study, with no evidence of increased benefit.

229 In the vitrectomy subgroup, mean BCVA increased (P = .01) and C

230 These results confirm that vitrectomy substantially increases vitreous pO2.

231 Prior to the invention of pars plana vitrectomy, such surgery was innovative, even daring.

232 vitreous during office-based micro-incision vitrectomy surgery (MIVS) assessing whether the bacteria

233 e dexamethasone (Ozurdex) at the time of (1) vitrectomy surgery and (2) silicone oil removal.

234 Phakic status and previous vitrectomy surgery do not appear to influence these valu

235 This occurred within 5 to 10 weeks following vitrectomy surgery with endolaser and silicone oil tampo

236 ary anatomic success rate in eyes undergoing vitrectomy surgery with silicone oil for PVR.

237 A total of 140 patients requiring vitrectomy surgery with silicone oil for retinal detachm

238 sed factors affecting the odds of undergoing vitrectomy surgery.

239 ained during all visits.Seven days after the vitrectomy, the spectral-domain optical coherence tomogr

240 e associated with developing an MH requiring vitrectomy; the effect varies across ages differently fo

241 (2%) progressed to stage 4 ROP and required vitrectomies to reattach the retinas.

242 , 1.92 logMAR; range, 0.8-2.7 logMAR) before vitrectomy to 0.72 logMAR (mean, 0.88 logMAR; range, -0.

243 ntrol subjects (n = 3) undergoing pars plana vitrectomy to remove an epiretinal membrane (ERM), and t

244 Vitrectomy usage is higher than that recommended from th

245 1260 procedures in 2014 (P < 0.01), whereas vitrectomy use for retinal detachment increased from 13

246 One year after vitrectomy, VA, CST, and MD improved in study eyes but n

247 Rates of vitrectomy varied across states, with California having

248 eon should balance the risks and benefits of vitrectomy versus scleral buckle and keep in mind that t

249 The average age of those undergoing vitrectomy was 57+/-13 years.

250 With regard to management, pars plana vitrectomy was associated with increased probability of

251 g 2 eyes had vitreous hemorrhage; endoscopic vitrectomy was done in them to detect an inoperable reti

252 ence, 372 dB; 95% CI, 213-531 dB; P < .001), vitrectomy was more frequent (15% vs 4%; difference, 9%;

253 Vitrectomy was not predictive of final visual acuity (ad

254 Vitrectomy was performed in 2 patients, and in 1 of thes

255 Vitrectomy was performed in 279 cases (45%), including 2

256 Vitrectomy was performed when vitreous inflammation was

257 A 23-gauge pars plana vitrectomy was performed with peeling of the inner limit

258 A 25-gauge posterior vitrectomy was performed, and the tube was returned to i

259 rior capsule was absent or torn-and anterior vitrectomy was performed.

260 dian of 1 (mean, 1.5; range, 1-3) additional vitrectomy was performed.

261 th proliferative diabetic retinopathy (PDR), vitrectomy was resorted for non clearing vitreous hemorr

262 Subretinal injection with pars plana vitrectomy was well tolerated in this cohort.

263 racapsular cataract extraction, and anterior vitrectomy, was done in all eyes as the primary stage.

264 eous biopsy, followed by 25-gauge pars plana vitrectomy, was performed in the same sitting in all cas

265 iERMs obtained during uneventful vitrectomies were cultivated ex vivo under adherent cond

266 The odds of undergoing a vitrectomy were 17% greater for black persons (adjusted

267 nterface abnormalities or that had undergone vitrectomy were excluded.

268 hemorrhage within 48 hours of the end of the vitrectomy were identified as the delayed suprachoroidal

269 e was unsuccessful, necessitating pars plana vitrectomy, while in a case with proliferative diabetic

270 Pars plana vitrectomy will probably remain the treatment of choice

271 eal injections of antibiotics and pars plana vitrectomies with intravitreal antibiotics.

272 lar holes that underwent 23-gauge pars plana vitrectomy with 2 cc pure SF6 gas tamponade.

273 Either pars plana vitrectomy with 24-gray EMB and ongoing pro re nata (PRN

274 dy with a stage IV FTMH underwent pars plana vitrectomy with 25 gauge plus transconjunctival system,

275 nal detachment repair shifted further toward vitrectomy with a distribution of 83% vitrectomy, 5% scl

276 Eleven underwent vitrectomy with a median time to intervention of 35.1 we

277 Vitrectomy with a supplemental buckle had an increased f

278 Those who underwent vitrectomy with a supplemental scleral buckle (n = 488)

279 Pars plana vitrectomy with creation of an inner retinal fenestratio

280 519 eyes (among 463 patients) that underwent vitrectomy with delamination, the intraoperative complic

281 In glaucomatous eyes, pars plana vitrectomy with epiretinal and internal limiting membran

282 Pars plana vitrectomy with ERM removal and ILM peeling was performe

283 papillary laser photocoagulation followed by vitrectomy with gas tamponade for creation of a permanen

284 al detachment, before and for 10 years after vitrectomy with gas.

285 Two eyes in the PPV group required a third vitrectomy with heavy silicone oil tamponade.

286 ary (CSB) recover visual acuity faster after vitrectomy with ILM peeling for ERM.

287 hod included 23-gauge or 25-gauge pars plana vitrectomy with induction of posterior vitreous detachme

288 A vitrectomy with internal limiting membrane peeling and a

289 antibiotic injection (n = 12) and pars plana vitrectomy with intravitreal antibiotic injection (n = 2

290 antibiotic injection (n = 5) and pars plana vitrectomy with intravitreal antibiotic injection (n = 5

291 is smaller than four disc areas, pars plana vitrectomy with intravitreal injection of antibiotics wi

292 A pars plana vitrectomy with intravitreal injection of ceftazidime (2

293 Vitrectomy with membrane peeling was the most common pro

294 Pars plana vitrectomy with or without delamination/segmentation.

295 These data also suggest that vitrectomy with removal of DEX may not be necessary in a

296 Vitrectomy with subretinal t-PA injection and gas tampon

297 hic full-thickness macular hole (FTMH) after vitrectomy with the inverted internal limiting membrane

298 Cumulative probability of vitrectomy within 16 weeks.

299 outcomes between the individuals undergoing vitrectomy within 3 months of the inciting event, 0.08+/

300 420 eyes (among 408 patients) that underwent vitrectomy without delamination, the intraoperative comp